Biogen plunges 30% after FDA panel votes against Alzheimer's drug

Wall Street analysts largely believe the panel’s near-unanimous votes against the drug, aducanumab, make it difficult for the FDA to go against the panel. “Approving aducanumab, in the face of such an overwhelmingly negative vote and commentary, is virtually impossible and would destroy the agency’s reputation at a very tenuous time for the regulator, ahead of potential actions on COVID vaccines,” Baird analyst Brian Skorney said. The FDA is expected to make its decision on aducanumab by March and is not obligated to follow the recommendations of the panel, but usually does. …read more

Source:: Yahoo Finance

      

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.